A multicenter randomized phase II DURABLE trial reported evidence that a maintenance regimen of durvalumab plus anlotinib outperforms durvalumab monotherapy in extensive-stage small-cell lung cancer (ES-SCLC). The study also evaluated biomarker-linked activity alongside efficacy and safety. The trial’s design compared dual-agent maintenance against durvalumab alone, focusing on outcomes consistent with typical second-line/post-induction maintenance decision points in ES-SCLC. Investigators highlighted biomarker profiles in addition to clinical endpoints. Clinically, the update matters because ES-SCLC remains an area with limited durable options, and maintenance strategies are often where marginal gains can translate into meaningful survival differences. The next step will be how these data align with ongoing confirmatory efforts and whether the biomarker signals can refine patient selection. While full statistical details weren’t included in the brief, the headline result is a clear directional tilt toward the combination approach under the DURABLE protocol.